Alterity Therapeutics Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATHE Nasdaq 2830 alteritytherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alterity Therapeutics Limited

3 Promising ASX Penny Stocks With Market Caps Over A$20M - Mar 12th, 2025 2:05 am
Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires - Mar 10th, 2025 9:28 pm
Alterity Therapeutics Raises A$40.0 million in Placement - Feb 10th, 2025 12:25 pm
Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year - Jan 30th, 2025 9:58 pm
Top Midday Gainers - Jan 30th, 2025 6:45 pm
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy - Jan 30th, 2025 12:35 pm
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report - Jan 24th, 2025 12:35 pm
Alterity CEO says ‘filled with optimism for 2025’ - Jan 10th, 2025 12:35 pm
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - Jan 9th, 2025 12:25 pm
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - Dec 4th, 2024 12:35 pm
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Nov 19th, 2024 12:25 pm
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - Nov 12th, 2024 12:35 pm
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - Nov 6th, 2024 12:35 pm
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report - Oct 31st, 2024 11:35 am
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 - Oct 14th, 2024 11:35 am
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - Oct 11th, 2024 11:35 am
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® - Oct 2nd, 2024 11:35 am
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer - Sep 30th, 2024 11:35 am
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® - Sep 23rd, 2024 11:35 am
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report - Jul 31st, 2024 11:35 am